Company news
Seres Therapeutics, Inc. (NASDAQ:MCRB) news
Every Seres Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoin...
August 5, 2026
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC...
July 8, 2026
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cas...
June 5, 2026
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
May 12, 2026
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 5, 2026
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live B...
May 4, 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
April 20, 2026
Seres Therapeutics to Present at CARB-X Investor Day
April 9, 2026
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 12, 2026
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
March 2, 2026
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
February 12, 2026
Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of Finance
January 13, 2026
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action a...
January 6, 2026
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
November 24, 2025
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 5, 2025
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
October 30, 2025
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
October 29, 2025
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in...
October 14, 2025
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actio...
September 23, 2025
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
August 27, 2025
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
July 22, 2025
Seres Therapeutics Announces Leadership Transition
July 22, 2025
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
May 27, 2025
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Tre...
April 29, 2025
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
April 23, 2025
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 13, 2025
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
March 4, 2025
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
March 3, 2025
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
January 16, 2025
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
January 9, 2025
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing A...
December 9, 2024
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
September 30, 2024
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
September 26, 2024
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogene...
September 12, 2024
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 13, 2024
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
August 6, 2024
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 7, 2024
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
June 6, 2024
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8, 2024
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
May 6, 2024
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
April 9, 2024
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 5, 2024
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
February 26, 2024
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
January 9, 2024
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH ...
December 7, 2023
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
November 2, 2023